Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Catumaxomab, a trifunctional IgG2 antibody with mouse and rat heavy and light chain components, targets human EpCAM and CD3 receptors. Its Fc region exhibits affinity for FcγRI (CD64), FcγRIIA (CD32a), and FcγRIII (CD16), making it a valuable tool in epithelial cancer anti-tumor research [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Catumaxomab, a trifunctional IgG2 antibody with mouse and rat heavy and light chain components, targets human EpCAM and CD3 receptors. Its Fc region exhibits affinity for FcγRI (CD64), FcγRIIA (CD32a), and FcγRIII (CD16), making it a valuable tool in epithelial cancer anti-tumor research [1] [2]. |
In vitro | Catumaxomab (0-5 ng/mL; 3-7 days) markedly inhibited the growth of FaDu tumor spheroids co-cultured with PBMCs in a dose-dependent manner [2]. |
Molecular Weight | N/A |
CAS No. | 509077-98-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Catumaxomab 509077-98-9 inhibitor inhibit